Products
Tisotumab Vedotin Biosimilar Antibody-Drug Conjugate (Tissue Factor) for Research
Pre-made Tisotumab Vedotin benchmark antibody (Whole mAb ADC, anti-F3 therapeutic antibody, Anti-CD142/TF/TFA Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1024-1mg | 1mg | 4635 |
| GMP-Bios-INN-1024-10mg | 10mg | |
| GMP-Bios-INN-1024-100mg | 100mg | |
| GMP-Bios-INN-1024-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tisotumab Vedotin Biosimilar, Whole Mab Adc, Anti-F3 Antibody: Anti-CD142/TF/TFA therapeutic antibody Drug Conjugate |
| INN Name | Tisotumab Vedotin |
| Target | F3 |
| Format | Whole mAb ADC |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Genmab A/S (Copenhagen Denmark) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - F3
1. Protein Tissue factor
2. Gene F3
3. Organism Homo sapiens (Human)
Function
Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited proteolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade.
